418 related articles for article (PubMed ID: 30027227)
21. Increasing rates of referrals for investigation of primary aldosteronism at a tertiary centre.
Park W; Whitfield P; Corley B; Harper S; Feltham J; Carroll R
N Z Med J; 2023 Nov; 136(1585):73-84. PubMed ID: 37956358
[TBL] [Abstract][Full Text] [Related]
22. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
Marzano L; Colussi G; Sechi LA; Catena C
Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
[TBL] [Abstract][Full Text] [Related]
23. Personalized Treatment of Patients With Primary Aldosteronism.
Obeid H; Chen Cardenas SM; Khairi S; Turcu AF
Endocr Pract; 2023 Jun; 29(6):484-490. PubMed ID: 36273684
[TBL] [Abstract][Full Text] [Related]
24. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
25. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.
Kline GA; Pasieka JL; Harvey A; So B; Dias VC
Ann Surg Oncol; 2013 Jul; 20(7):2274-8. PubMed ID: 23504117
[TBL] [Abstract][Full Text] [Related]
26. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.
Rossi GP; Cesari M; Cuspidi C; Maiolino G; Cicala MV; Bisogni V; Mantero F; Pessina AC
Hypertension; 2013 Jul; 62(1):62-9. PubMed ID: 23648698
[TBL] [Abstract][Full Text] [Related]
27. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
28. Quality of life in primary aldosteronism: A prospective observational study.
Buffolo F; Cavaglià G; Burrello J; Amongero M; Tetti M; Pecori A; Sconfienza E; Veglio F; Mulatero P; Monticone S
Eur J Clin Invest; 2021 Mar; 51(3):e13419. PubMed ID: 32997795
[TBL] [Abstract][Full Text] [Related]
29. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years.
Wu VC; Chueh SJ; Chen L; Chang CH; Hu YH; Lin YH; Wu KD; Yang WS;
J Hypertens; 2017 Aug; 35(8):1698-1708. PubMed ID: 28661412
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Satoh M; Maruhashi T; Yoshida Y; Shibata H
Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Primary Aldosteronism Reduces the Probability of Obstructive Sleep Apnea.
Wang E; Chomsky-Higgins K; Chen Y; Nwaogu I; Seib CD; Shen WT; Duh QY; Suh I
J Surg Res; 2019 Apr; 236():37-43. PubMed ID: 30694777
[TBL] [Abstract][Full Text] [Related]
32. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
[TBL] [Abstract][Full Text] [Related]
33. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
34. Factors affecting parathyroid hormone levels in different types of primary aldosteronism.
Jiang Y; Zhang C; Ye L; Su T; Zhou W; Jiang L; Zhang Y; Wang W
Clin Endocrinol (Oxf); 2016 Aug; 85(2):267-74. PubMed ID: 26589237
[TBL] [Abstract][Full Text] [Related]
35. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
[TBL] [Abstract][Full Text] [Related]
36. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism.
Wada N; Shibayama Y; Umakoshi H; Ichijo T; Fujii Y; Kamemura K; Kai T; Sakamoto R; Ogo A; Matsuda Y; Fukuoka T; Tsuiki M; Suzuki T; Naruse M
J Hum Hypertens; 2017 Oct; 31(10):627-632. PubMed ID: 28540931
[TBL] [Abstract][Full Text] [Related]
37. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
[TBL] [Abstract][Full Text] [Related]
38. Primary aldosteronism: diagnostic and therapeutic considerations.
Nishizaka MK; Calhoun DA
Curr Cardiol Rep; 2005 Nov; 7(6):412-7. PubMed ID: 16256009
[TBL] [Abstract][Full Text] [Related]
39. Risk of dementia in primary aldosteronism compared with essential hypertension: a nationwide cohort study.
Hong N; Kim KJ; Yu MH; Jeong SH; Lee S; Lim JS; Rhee Y
Alzheimers Res Ther; 2023 Aug; 15(1):136. PubMed ID: 37568223
[TBL] [Abstract][Full Text] [Related]
40. Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation.
Nguyen V; Tu TM; Mamauag MJB; Lai J; Saffari SE; Aw TC; Ong L; Foo RSY; Chai SC; Fones S; Zhang M; Puar TH
Front Endocrinol (Lausanne); 2022; 13():869980. PubMed ID: 35518929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
